Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:43 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease
NCT02472665 · Grifols Therapeutics LLC · PHASE4 · withdrawn · last registry update 2026-05-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to recruitment difficulties for pediatric patients. The reason for study cancellation is not related to safety concerns or any adverse events.” | – | Registry record, Grifols Therapeutics LLC |
Also happening at the time. Not shown to be a cause.
No drug target was found for this trial's interventions, so there is no same-target timeline.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision